KR102533637B1 - 화합물과 푸마르산의 결정체, 코로나바이러스 유발 질환의 치료를 위한 약학적 조성물 및 방법 - Google Patents

화합물과 푸마르산의 결정체, 코로나바이러스 유발 질환의 치료를 위한 약학적 조성물 및 방법 Download PDF

Info

Publication number
KR102533637B1
KR102533637B1 KR1020220147414A KR20220147414A KR102533637B1 KR 102533637 B1 KR102533637 B1 KR 102533637B1 KR 1020220147414 A KR1020220147414 A KR 1020220147414A KR 20220147414 A KR20220147414 A KR 20220147414A KR 102533637 B1 KR102533637 B1 KR 102533637B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
active ingredient
present
weight
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020220147414A
Other languages
English (en)
Korean (ko)
Inventor
웨이예 웨이
지아난 양
씨아오타오 우
타오타오 자오
하오 왕
차오 리
레이 추
빈 왕
Original Assignee
베이징 그랜드 조하무 파마슈티칼 컴퍼니 리미티드
난징 그리트파마 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=86385250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102533637(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CN202210500296.8A external-priority patent/CN114591304B/zh
Priority claimed from CN202210644417.6A external-priority patent/CN114716417B/zh
Priority claimed from CN202211119888.1A external-priority patent/CN115252619B/zh
Application filed by 베이징 그랜드 조하무 파마슈티칼 컴퍼니 리미티드, 난징 그리트파마 컴퍼니 리미티드 filed Critical 베이징 그랜드 조하무 파마슈티칼 컴퍼니 리미티드
Application granted granted Critical
Publication of KR102533637B1 publication Critical patent/KR102533637B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
KR1020220147414A 2022-05-10 2022-11-07 화합물과 푸마르산의 결정체, 코로나바이러스 유발 질환의 치료를 위한 약학적 조성물 및 방법 Active KR102533637B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN202210500296.8A CN114591304B (zh) 2022-05-10 2022-05-10 一种化合物的结晶形式及其制备方法和用途
CN2022105002968 2022-05-10
CN202210644417.6A CN114716417B (zh) 2022-06-09 2022-06-09 化合物与富马酸的结晶形式的原料药及其药物组合物和用途
CN2022106444176 2022-06-09
CN2022111198881 2022-09-15
CN202211119888.1A CN115252619B (zh) 2022-05-27 2022-09-15 药物组合物及其制备方法和用于治疗冠状病毒引起的疾病的用途

Publications (1)

Publication Number Publication Date
KR102533637B1 true KR102533637B1 (ko) 2023-05-16

Family

ID=86385250

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020220147414A Active KR102533637B1 (ko) 2022-05-10 2022-11-07 화합물과 푸마르산의 결정체, 코로나바이러스 유발 질환의 치료를 위한 약학적 조성물 및 방법

Country Status (3)

Country Link
US (1) US11655240B1 (enExample)
JP (3) JP7669325B2 (enExample)
KR (1) KR102533637B1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230302005A1 (en) * 2022-03-25 2023-09-28 Beijing Grand Johamu Pharmaceutical Company, Ltd. Active pharmaceutical ingredient, preparation method thereof, and pharmaceutical composition including the same
US20230365536A1 (en) * 2022-05-10 2023-11-16 Beijing Grand Johamu Pharmaceutical Company, Ltd. Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130138734A (ko) * 2010-08-10 2013-12-19 시오노기 앤드 컴파니, 리미티드 트라이아진 유도체 및 그것을 함유하는 진통 작용을 갖는 의약 조성물
KR20210153908A (ko) * 2020-06-11 2021-12-20 제이더블유중외제약 주식회사 코로나바이러스감염증-19(covid-19) 치료용 조성물
KR20210158795A (ko) * 2020-06-24 2021-12-31 뉴지랩파마 주식회사 나파모스타트 메실레이트를 유효성분으로 포함하는 경구용 약제학적 조성물
KR20220142999A (ko) * 2021-04-14 2022-10-24 시오노기 앤드 컴파니, 리미티드 바이러스 증식 저해 작용을 갖는 트라이아진 유도체 및 그들을 함유하는 의약 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101214242A (zh) 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
WO2008143239A1 (ja) 2007-05-21 2008-11-27 Toray Industries, Inc. 結晶性微粉化粒子
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
CN101596189A (zh) 2008-06-05 2009-12-09 上海艾力斯生物医药有限公司 含有咪唑-5-羧酸类衍生物的药用组合物
EP2468762A1 (en) * 2010-11-30 2012-06-27 Dr. Falk Pharma Gmbh Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN106994121B (zh) 2016-01-26 2021-07-02 江苏恒瑞医药股份有限公司 一种用于治疗癌症的药物组合物
JP6630229B2 (ja) 2016-05-17 2020-01-15 エルメッド株式会社 レベチラセタム含有医薬組成物及びその製造方法
WO2021183774A1 (en) 2020-03-12 2021-09-16 Angion Biomedica Corp. Treating acute respiratory distress
CN113521289A (zh) 2020-04-16 2021-10-22 中国科学院上海药物研究所 15种药物有效成分在抗病毒感染中的应用
WO2021226561A1 (en) 2020-05-07 2021-11-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Covid-19 therapeutics and methods of treatment
AU2021289665A1 (en) 2020-06-10 2022-12-15 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
WO2022035911A2 (en) 2020-08-11 2022-02-17 Tutela Pharmaceuticals, Inc. Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
WO2022053993A2 (en) 2020-09-12 2022-03-17 Mylan Laboratories Limited Treatments for sars-cov-2 infection (covid-19)
CN113198019A (zh) 2021-05-06 2021-08-03 叶绍朋 用于新冠状病毒肺炎感染初期治疗的药物组方
EP4289432A4 (en) 2021-11-24 2025-01-15 Shionogi & Co., Ltd PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES
CN114716417B (zh) 2022-06-09 2022-09-20 北京远大九和药业有限公司 化合物与富马酸的结晶形式的原料药及其药物组合物和用途
CN117069706A (zh) 2022-05-10 2023-11-17 北京远大九和药业有限公司 一种化合物的结晶形式及其制备方法和用途
CN114948969B (zh) 2022-05-27 2022-12-23 北京远大九和药业有限公司 包含化合物与富马酸的结晶形式的药物组合物及其制备方法和用途
CN117159555A (zh) 2022-05-27 2023-12-05 北京远大九和药业有限公司 药物组合物及其制备方法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130138734A (ko) * 2010-08-10 2013-12-19 시오노기 앤드 컴파니, 리미티드 트라이아진 유도체 및 그것을 함유하는 진통 작용을 갖는 의약 조성물
KR20210153908A (ko) * 2020-06-11 2021-12-20 제이더블유중외제약 주식회사 코로나바이러스감염증-19(covid-19) 치료용 조성물
KR20210158795A (ko) * 2020-06-24 2021-12-31 뉴지랩파마 주식회사 나파모스타트 메실레이트를 유효성분으로 포함하는 경구용 약제학적 조성물
KR20220142999A (ko) * 2021-04-14 2022-10-24 시오노기 앤드 컴파니, 리미티드 바이러스 증식 저해 작용을 갖는 트라이아진 유도체 및 그들을 함유하는 의약 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yuto Unoh et al. Journal of Medicinal Chemistry. 2022, Vol. 65, pp. 6499-9512* *

Also Published As

Publication number Publication date
JP7669325B2 (ja) 2025-04-28
JP2023166957A (ja) 2023-11-22
JP2024045113A (ja) 2024-04-02
US11655240B1 (en) 2023-05-23
JP2024056678A (ja) 2024-04-23

Similar Documents

Publication Publication Date Title
DK168423B1 (da) Stabilt, presset farmaceutisk præparat og fremgangsmåde til fremstilling deraf.
JP2018184410A (ja) 非晶質ダパグリフロジンを含有する製剤
JP2006514052A (ja) 吸湿性および／または潮解性の薬剤を含む固体分散剤
KR102533637B1 (ko) 화합물과 푸마르산의 결정체, 코로나바이러스 유발 질환의 치료를 위한 약학적 조성물 및 방법
JP5174909B2 (ja) 活性成分のコーティング膜が保護される口腔内崩壊剤形を製造するための組成物
CN115252619B (zh) 药物组合物及其制备方法和用于治疗冠状病毒引起的疾病的用途
US20230365536A1 (en) Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases
US20230302005A1 (en) Active pharmaceutical ingredient, preparation method thereof, and pharmaceutical composition including the same
EP2263671B1 (en) Amide derivative-containing pharmaceutical composition
JP2006206612A (ja) 固形製剤用組成物
CN114716417A (zh) 化合物与富马酸的结晶形式的原料药及其药物组合物和用途
EP3731817B1 (en) Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
WO2010084637A1 (ja) 崩壊性及び溶出性に優れた内服用錠剤
CN114948969B (zh) 包含化合物与富马酸的结晶形式的药物组合物及其制备方法和用途
CN118178409A (zh) 一种艾沙康唑药物组合物及其制备方法
WO2020111089A1 (ja) 医薬組成物
JP2014080368A (ja) リマプロストとβ−シクロデキストリンを含有する錠剤
JP2005314413A (ja) 経口投与用医薬組成物
EP4081193A1 (en) Composition for the preparation of perindopril arginine granules, a method for their preparation and pharmaceutical composition comprising the granules
JP3646310B1 (ja) 経口投与用医薬組成物
JP2020183382A (ja) フィンゴリモド塩酸塩含有製剤及びフィンゴリモド塩酸塩含有製剤の製造方法
JP3934150B1 (ja) 固形製剤および製剤組成物
WO2023172958A1 (en) Stable formulations of talabostat
CA3256768A1 (en) PHARMACEUTICAL COMPOSITION OF BEMPEDOIC ACID
JP2007169264A (ja) 固形製剤および製剤組成物

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20250731

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2533637

Appeal request date: 20231027

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2023100003461